ArticleCancer science2018

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.

Akihiro Hirakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.